Bone morphogenetic proteins (BMPs) function in most tissues but have cell type-specific effects. Given the relatively small number of BMP receptors, this exquisite signaling specificity requires additional molecules to regulate this pathway's output. The receptor tyrosine kinase MuSK (muscle-specific kinase) is critical for neuromuscular junction formation and maintenance. Here, we show that MuSK also promotes BMP signaling in muscle cells. MuSK bound to BMP4 and related BMPs with low nanomolar affinity in vitro and to the type I BMP receptors ALK3 and ALK6 in a ligand-independent manner both in vitro and in cultured myotubes. High-affinity binding to BMPs required the third, alternatively spliced MuSK immunoglobulin-like domain. In myoblasts, endogenous MuSK promoted BMP4-dependent phosphorylation of SMADs and transcription of Id1, which encodes a transcription factor involved in muscle differentiation. Gene expression profiling showed that MuSK was required for the BMP4-induced expression of a subset of genes in myoblasts, including regulator of G protein signaling 4 (Rgs4). In myotubes, MuSK enhanced the BMP4-induced expression of a distinct set of genes, including transcripts characteristic of slow muscle. MuSK-mediated stimulation of BMP signaling required type I BMP receptor activity but was independent of MuSK tyrosine kinase activity. MuSK-dependent expression of Rgs4 resulted in the inhibition of Ca 2+ signaling induced by the muscarinic acetylcholine receptor in myoblasts. These findings establish that MuSK has dual roles in muscle cells, acting both as a tyrosine kinasedependent synaptic organizing molecule and as a BMP co-receptor that shapes BMP transcriptional output and cholinergic signaling.
INTRODUCTION
Bone morphogenetic proteins (BMPs) function in virtually all tissues in developing and mature organisms, and cell type-specific output of BMP signaling is essential for proper tissue function and differentiation. However, the large BMP family is served by only a handful of BMP receptors. Thus, signaling specificity in distinct cellular and developmental contexts requires additional molecules to modulate pathway output. Here, we identify a muscle-specific kinase (MuSK) as a co-receptor that potentiates BMP signaling in myogenic cells.
BMPs are a large subfamily of conserved signaling molecules within the transforming growth factor-b (TGFb) superfamily. Two different classes of receptors, type I (ALK2, ALK3, or ALK6) and type II (BMPRII, ActRIIB, and ActRII), bind BMPs on the cell surface (1, 2) . After ligand binding, the type I receptor is phosphorylated by the constitutively active type II receptor (2) . The activated type I receptor phosphorylates small mothers against decapentaplegic 1 (SMAD1), SMAD5, or SMAD8, which then associates with SMAD4 (3). This complex translocates to the nucleus where it can function as part of the transcriptional activator or repressor complexes in a cell type-specific fashion (4, 5) . For example, BMP4 induces osteoblast differentiation but inhibits myoblast differentiation (6, 7) .
The canonical BMP signaling pathway is modulated at several levels. The best understood mechanism is the control of ligand availability by either secreted or cell surface-associated BMP-binding molecules. For example, the secreted proteins noggin, chordin, and members of the DAN (differential screening-selected gene in neuroblastoma) family sequester BMPs and prevent their association with signaling receptors (8) . The glycophosphatidylinositol-anchored RGM/Dragon family co-receptors bind BMPs and positively regulate signaling, whereas the transmembrane protein BAMBI (BMP and activin membrane-bound inhibitor) acts as a type I pseudoreceptor to inhibit BMP signaling (9) . BMP pathway modulators can also act in SMAD-dependent and SMAD-independent manners (10, 11) . Finally, receptor tyrosine kinases (RTKs) such as c-KIT and ROR-2 can modulate signaling by binding TGFß family ligands and receptors (12) .
MuSK is an RTK that is highly abundant at the postsynaptic membrane of the neuromuscular junction (NMJ) and is well established as the master regulator of the formation and maintenance of this synapse (13) (14) (15) . Proper signaling in this context requires neuronal agrin, low-density lipoprotein receptor-related protein 4 (LRP4), docking protein 7 (DOK7), and MuSK tyrosine kinase activity (13) . MuSK is also present outside the NMJ, notably in intact slow-twitch muscle, denervated fast-twitch muscle, and brain (16) (17) (18) . However, MuSK function in these nonsynaptic contexts is poorly understood.
Here, we report that MuSK binds BMPs and influences the BMP4-mediated gene expression signature in muscle cells. MuSK promoted the BMP4-induced phosphorylation of SMAD1/5/8 and expression of Id1, which encodes a transcriptional coactivator. In myoblasts, MuSK was required for the BMP4-induced expression of a subset of genes, including the guanosine triphosphatase (GTP)-activating protein (GAP) Rgs4. This MuSK-dependent, BMP4-responsive GAP regulated muscarinic acetylcholine receptor (mAChR)-mediated Ca 2+ signaling in these cells. In myotubes, MuSK stimulated the BMP4-induced expression of a large set of genes, including the slow muscle-enriched genes myosin heavy chain 15 (Myh15) and carbonic anhydrase 3 (Car3). MuSK bound to the type I BMP receptors ALK3 and ALK6 and the type I activin receptor ALK4 in a ligandindependent manner. Type I BMP receptor activity was necessary for the regulation of MuSK-dependent transcripts, but MuSK tyrosine kinase activity was dispensable. We propose that MuSK acts as a BMP co-receptor to confer cell type-specific signaling in muscle. These findings also establish that MuSK has dual roles in muscle cells, acting as both a tyrosine kinase-dependent synaptic organizing molecule and a BMP co-receptor that shapes transcriptional output and Ca 2+ signaling in myogenic cells.
RESULTS

MuSK binds to BMPs
Because both BMP4 and MuSK are important for muscle differentiation (19) , we tested whether MuSK and BMP interact in vitro. We preincubated purified BMP4 with the His-tagged MuSK ectodomain (Fig. 1A ) or a control protein (His-tagged tobacco etch virus protease). After depletion of the tagged MuSK or control protein with nickel beads, we assessed BMP4 activity in the supernatants using a cell line harboring a luciferase reporter gene under the control of the BMP-responsive elements of the Id1 promoter [C2C12BRA (20) ]. Luciferase activity in the supernatants was reduced about 50%, indicating that BMP4 had coprecipitated with MuSK on the nickel beads (Fig. 1B) . We observed no significant inhibition of BMP4 activity with the control protein. Enzyme-linked immunosorbent assay (ELISA) analysis of the bead-containing pellets confirmed the specific pull-down of BMP4 by MuSK (Fig. 1C) . Thus, BMP4 and MuSK bind in solution.
To determine the kinetics and binding affinity of the MuSK-BMP4 interaction, we used surface plasmon resonance (SPR). BMP4 was immobilized as the ligand, and the MuSK ectodomain was used as the analyte. A kinetic analysis using a heterogeneous ligand model revealed highaffinity binding between these molecules, with a dissociation constant (K d ) of 6.1 nM, similar in magnitude to the high-affinity interaction of BMP2 with its type I receptors ( Fig. 1D and table S1 ) (21) . We also used SPR to determine whether the MuSK ectodomain binds to the closely related family members BMP2 and BMP7 (22, 23) . These proteins bound MuSK with comparable affinity to BMP4 (5.6 and 11.8 nM for BMP2 and BMP7, respectively) ( fig. S1 and table S1). Thus, the MuSK ectodomain binds with high affinity to a closely related set of the BMP family members that includes BMP2, BMP4, and BMP7.
As a further test of the interaction between MuSK and BMP4, we treated C2C12BRA cells either with BMP4 alone or with purified recombinant MuSK ectodomain. Coincubation with 50 or 100 nM MuSK ectodomain inhibited BMP4-induced luciferase activity by 50% ( fig. S2 ). In contrast, no inhibition was observed with the His-tagged control protein (200 nM; fig. S2 ). Thus, the MuSK ectodomain inhibits the BMP4-induced activation of the Id1 reporter in this cell line, possibly by sequestering BMP4.
The Ig3 domain of MuSK is required for high-affinity BMP4 binding
We next determined which regions of the MuSK extracellular domain were required for binding to BMP4. One candidate domain was suggested by MuSK alternative splicing. A major splice isoform of MuSK lacks the Ig3 domain in the extracellular portion of the molecule. The biological importance of this DIg3 form of MuSK has been unclear because the naturally occurring splice form with an intact cytoplasmic domain is sufficient for forming postsynaptic specializations in muscle cells in culture and in vivo (24) . To test the potential role of this domain in MuSK-BMP4 binding, we generated constructs encoding Fc-fusion ectodomain proteins either containing or lacking the Ig3 domain (FL and DIg3, respectively; Fig.  1E ) and tested their binding to soluble BMP4 over a range of concentrations. BMP4 displayed saturable, high-affinity binding to FL-ecto-MuSK with a half maximum of~30 nM (Fig. 1F) . In contrast, only low, nonsaturable BMP4 binding was observed with DIg3-ecto-MuSK.
We considered the possibility that the failure to observe specific binding of BMP4 to Fc-DIg3-ecto-MuSK might be due to artifactual misfolding of the ectodomain. To control for such potential misfolding, we assessed the binding of both proteins to biglycan, which associates with MuSK in a manner that is independent of the Ig3 domains (25) . Biglycan bound equivalent amounts of both the FL-ecto-MuSK and DIg3-ecto-MuSK proteins ( fig. S3 ). Together, these data indicate that the alternatively spliced Ig3 domain is necessary for MuSK binding to BMP4.
MuSK affects the expression of distinct sets of BMP4-induced genes in myoblasts
BMPs are potent and selective regulators of gene transcription. We therefore determined whether MuSK modulates BMP-induced gene transcription in myogenic cells. As a first test of this possibility, we treated either wild-type or MuSK −/− myoblasts with BMP4 and analyzed their gene expression profiles using microarrays. We identified 120 transcripts that increased in abundance in wild-type but not in MuSK −/− cells after BMP4 treatment [≥1.5-fold; false discovery rate (FDR)-corrected P < 0.05]. Thus, these BMP-regulated transcripts are MuSK-dependent ( Fig. 2A and  table S2 ). In addition, 67 transcripts increased in abundance both in wildtype and MuSK −/− myoblasts and, therefore, were not qualitatively regulated by MuSK ( Fig. 2A and table S3 ). Notably, many of the genes induced in both genotypes encoded proteins active in the canonical BMP pathway including Id1, Id2, and Id3 and Smad6, Smad7, and Smad9. Finally, 42 transcripts increased abundance only in MuSK −/− myoblasts ( Fig. 2A and  table S4 ).
Because the arbitrary fold change and statistical significance cutoffs might lead to false-positive hits in gene array studies, we validated the responses revealed by the microarrays for a subset of transcripts. Using quantitative reverse transcription polymerase chain reaction (qRT-PCR), the relative amount of transcripts of these genes was measured and normalized to 18S ribosomal RNA (rRNA). Fabp7, a previously unidentified BMP4 target, was prominent among the 67 MuSK-independent transcripts. qRT-PCR analysis showed that Fabp7 transcript abundance increased more than 15-fold between untreated and treated wild-type myoblasts, as well as between untreated and treated MuSK −/− myoblasts, after an 8-hour BMP4 treatment (Fig. 2B) . Next, we validated a group of MuSK-dependent genes. BMP4 selectively increased the expression of Ptgs2 and Ptger4 in wild-type as compared to MuSK −/− myoblasts (Fig.  2, C and D) . Ptger2 encodes cyclooxygenase-2 (COX2), the key enzyme in the prostaglandin pathway, and Ptger4 encodes a prostaglandin receptor. BMP4 also induced an eightfold increase in the expression of Rgs4, a regulator of heterotrimeric guanine nucleotide-binding protein (G protein) signaling, in wild-type cells, but this transcript did not change in abundance in MuSK −/− cells (Fig. 2E) . Finally, Rgs4 also showed a strict MuSK dependence when cells were stimulated with BMP4 for a shorter period (2 hours; fig. S4 wild-type myotubes, whereas 62 transcripts increased in abundance in both genotypes ( Fig. 3A and tables S5 and S6). Further 140 transcripts increased abundance only in MuSK −/− myotubes ( Fig. 3A and table S7). Finally, a comparison of transcripts that increased in wild-type myoblasts and myotubes in a manner that depended on both BMP4 and MuSK revealed 113 and 70 transcripts in these cell types, respectively, with only 12 common to both ( Fig. 3B and tables S8 to 10). Together, these results indicate that MuSK regulates transcriptional output of the BMP pathway in myoblasts and myotubes in a cell type-specific manner.
We then analyzed the MuSK-dependent BMP4 responses in myoblasts and myotubes according to gene functions and localization patterns in the cell. These transcripts included a large number of signaling molecules; thus, we first manually attributed each MuSK-dependent transcriptional response to a functional or localization-based category related to signaling. This analysis demonstrated that half of these specific responses in myoblasts and more than half of those in myotubes affected signaling-related molecules such as growth factors, transcription factors, cell surface receptors, extracellular matrix proteins, and intracellular signaling proteins 
MuSK affects the expression of genes expressed in slow-twitch muscle fibers
Although MuSK is abundant at the NMJ in all muscles, it is also localized extrasynaptically in slow-twitch, but not fast-twitch, muscle fibers (17) . These observations suggest that MuSK may have unique, nonsynaptic functions in slow muscle. One possibility is that MuSK could play a role in regulating the expression of slow muscle-specific genes. Examination of the microarray data revealed the MuSK-dependent and BMP4-induced up-regulation of Myh15 and Car3, both of which have been previously suggested to be slow-type fiber markers (26, 27) . We validated the MuSKdependent regulation of these transcripts by qRT-PCR in cultured myotubes (Fig. 3C) . Finally, we confirmed that MuSK, Myh15, and Car3 were enriched in slow muscles as compared to fast muscles isolated from mice (soleus and extensor digitorum longus, respectively; Fig. 3D ). Notably, neither of these genes was up-regulated by BMP4 in myoblasts (Fig. 3C) , further reinforcing the cell type selectivity of MuSK-dependent transcription in the myogenic lineage. Together, these results suggest that MuSK selectively regulates the expression of transcripts expressed in slow muscle.
MuSK kinase activity is not required for modulating BMP4 signaling NMJ differentiation requires MuSK activation, as well as both an active MuSK tyrosine kinase domain and the juxtamembrane tyrosine in an NPXY motif at position 553 (28, 29) . We therefore investigated the role of MuSK tyrosine kinase activity in the regulation of BMP-induced transcription. As a first test, we determined whether BMP4 stimulated MuSK kinase activity. We treated wild-type myotubes with BMP4 for intervals ranging from 10 to 180 min and then assessed MuSK activation (phosphorylation). We detected no increase in MuSK tyrosine phosphorylation at any of these time points (Fig. 4A) . As a positive control, we observed robust MuSK kinase activation in parallel cultures treated with agrin for 60 min (Fig. 4A) . The time intervals and ligand concentrations in these experiments were the same as those used to demonstrate MuSK-dependent BMP-mediated transcription (Figs. 2 and 3) . Thus, BMP4 does not induce MuSK phosphorylation under conditions where it stimulates MuSK-dependent transcription. We next used a genetic approach to test the potential role of MuSK activation in BMP4-mediated transcription. We used MuSK −/− cell lines that had been stably transfected with constructs encoding wild-type, kinase-dead (K608A), or Y553F variants of MuSK. Previous work has shown that the wild-type mutants, but neither the kinase-dead nor Y553F mutants, are activated in response to agrin in these rescue lines (28, 29) . In agreement with the results presented previously (Fig. 2) , BMP4 did not increase Rgs4 expression in MuSK −/− myoblasts. However, all the MuSK transgenic cell lines-including those lacking kinase activity-showed robust BMP4-stimulated Rgs4 expression (Fig. 4B) . Together, these results demonstrate that MuSK is not activated by BMP4 and that its tyrosine kinase activity is dispensable for MuSK-dependent, BMP4-induced transcription.
MuSK-dependent gene regulation requires the activity of canonical BMP pathway members
We next explored the relationship between MuSK and the BMP signaling mediators. The core BMP pathway involves ligand activation of the type I and type II receptor complex followed by phosphorylation and translocation of SMAD1/5/8 to the nucleus, where it regulates transcription. We first examined the role of MuSK in SMAD phosphorylation. We treated either wild-type or MuSK −/− myoblasts with BMP4 and assessed SMAD phosphorylation by Western blotting (Fig. 5A , left panel). SMAD1/5/8 phosphorylation was reduced in MuSK −/− cells at all ligand concentrations tested (Fig. 5A, right panel) . These results indicate that MuSK enhances BMP signaling, at least in part, by promoting SMAD1/5/8 phosphorylation.
The attenuated phosphorylated SMAD1/5/8 response in MuSK −/− myoblasts suggested that canonical BMP-induced gene transcription might also be reduced. To test this possibility, we compared the abundance of Id1 transcripts after BMP stimulation in both wild-type and MuSK −/− myoblasts. Although Id1 transcripts were increased in both genotypes, there was a threefold greater response in the wild-type cells as compared to the MuSK −/− cells (Fig. 5B) . Thus, both BMP-induced changes in SMAD1/5/8 phosphorylation and Id1 transcript abundance are reduced in the absence of MuSK. We conclude that MuSK promotes canonical BMP signaling.
We next determined whether type I BMP receptor activity plays a role in regulating MuSK-dependent transcripts. We used a selective inhibitor of type I BMP receptors, LDN-193189 (30) . Treatment of myoblasts with this compound inhibited BMP4-induced up-regulation of Rgs4 expression (Fig. 5C) . As a control, we also examined the expression of the canonical BMP target Id1 and showed that BMP4-induced up-regulation of this transcript was also inhibited by LDN-193189 (Fig. 5D) . Thus, BMP4-induced up-regulation of MuSK-dependent transcripts requires type I BMP receptor activity.
MuSK binds to the type I BMP receptors ALK3 and ALK6 and the type I activin receptor ALK4
The ability of MuSK to quantitatively and qualitatively modulate the BMP signaling pathway in a tyrosine kinase-independent fashion (Fig. 5E ). In contrast, no specific binding was observed with ALK2, the type II receptors ActRIIB and BMPRII, or the tumor necrosis factor family receptor TROY. We also tested MuSK binding to ALK4, a type I activin receptor that is closely related to the type I BMP receptors ALK3 and ALK6. ALK4 bound MuSK in a high-affinity manner, similar to ALK6 (Fig. 5E) . Finally, to determine whether endogenous MuSK and BMP receptors associate in muscle cells, we prepared detergent extracts from cultured myotubes and immunoprecipitated ALK3 and ALK6. MuSK coimmunoprecipitated with ALK3, but not ALK6, under these conditions (Fig. 5F ). Therefore, we conclude that in myotubes, MuSK selectively associates with ALK3, one of the preferred type I receptors for BMP4 (1) .
Together, these data demonstrate that MuSK is a co-receptor for BMP in muscle cells. Finally, we asked whether MuSK regulates compartmentalization of the BMP signaling mediators SMAD1, SMAD5, and SMAD8. Immunostaining for phosphorylated SMAD1/5/8 revealed that the subcellular localization of these key BMP signaling components differed in wild-type and MuSK −/− myoblasts. In wild-type myoblasts, phosphorylated SMAD1/5/8 was distributed in abundant, distinctive puncta in over 70% of the cells (fig. S6, A and B) . In contrast, such phosphorylated SMAD1/5/8 puncta were sparse in MuSK −/− cells and could only be detected in~20% of the mutant cells. Together, these observations suggest that MuSK might favor cytoplasmic retention of phosphorylated SMAD1/5/8. signaling events, including Ca 2+ oscillations in the cytosol (31) . Therefore, we hypothesized that MuSK-dependent, BMP4-induced expression of Rgs4 may modulate Ca 2+ signaling (32) . To test this idea, we first treated wild-type myoblasts with the cholinergic agonist carbachol, which increases intracellular Ca 2+ concentration by activating G aq -coupled muscarinic receptors (33) . As expected, carbachol treatment increased intracellular Ca 2+ in resting myoblasts (Fig. 6A , upper panel images; blue trace in the graph on the right). In contrast, the carbachol-mediated Ca 2+ signal was attenuated in BMP4-treated myoblasts (Fig. 6A, lower panel images; green trace in the graph on the right). To test whether this reduction was due to the action of RGS4, we treated the myoblasts with the selective RGS4 inhibitor 11b (34) and analyzed their Ca 2+ responses with or without BMP4 pretreatment. BMP4 pretreatment did not alter the Ca 2+ response evoked by carbachol in myoblasts treated with the RGS4 inhibitor, suggesting that RGS4 mediates the reduction in carbachol-induced Ca 2+ response by BMP4 (Fig. 6, B and C) . Together, these results indicate that MuSK-dependent transcription of the BMP4-responsive gene Rgs4 mediates the inhibition of carbachol-induced Ca 2+ response in myoblasts. 
DISCUSSION
Here, we show that the RTK MuSK, previously established as the central organizer of the NMJ, binds BMPs and BMP receptors and shapes the transcriptional response to these factors in myogenic cells. We propose that MuSK acts as a tissue-specific BMP co-receptor that is required for the BMP-responsive transcription of a subset of genes in a cell contextdependent manner (Fig. 7) . Several observations indicate that MuSK is a BMP co-receptor (Figs. 1, 4 MuSK binds to BMP2, BMP4, and BMP7 with affinities ranging from 5.6 to 11.8 nM, which are comparable to the affinities with which BMPs bind to other physiologically relevant BMP-interacting molecules (11, 35) . Moreover, the presence of MuSK increases SMAD1/5/8 activation in response to a wide range of BMP4 concentrations, and the expression of transcripts encoding canonical BMP pathway components is greater in the presence of MuSK. These results indicate that MuSK is a positive regulator of canonical BMP signaling.
The role of MuSK in shaping the BMP-mediated transcriptional profile is marked. We observed 101 and 58 MuSK-dependent transcripts unique to myoblasts and myotubes, respectively (Figs. 2 and 3 and tables S3 and S6). The selectivity and robustness of this response are underscored by the comparison of MuSK-dependent and MuSK-independent transcripts (Fig. 2) . For example, BMP increased the abundance of Fabp7 >15-fold in either the presence or absence of MuSK. In contrast, BMP induced the expression of Rgs4 and Ptgs2 eight-and fourfold, respectively, in a manner that was strictly dependent on MuSK.
The BMP-MuSK pathway is likely to shape the transcriptional output through multiple mechanisms. Increased expression of Rgs4 was observed within 2 hours of BMP4 treatment, consistent with this gene being a direct target of MuSK-dependent BMP signaling. However, many transcription factors were also regulated in a MuSK-and BMP-dependent manner ( fig.  S5 ), suggesting that other MuSK-dependent, BMP4-induced transcripts are the product of a BMP-induced transcription factor cascade.
There are at least three, nonmutually exclusive mechanisms by which a MuSK co-receptor could regulate BMP signaling. First, MuSK could augment signaling by presenting a ligand to the BMP receptor complex. Second, MuSK may create subcellular signaling compartments that generate unique outputs, a mechanism supported by the distinct repertoire of MuSKdependent transcripts in myoblasts and myotubes (Figs. 2 and 3 ) and the presence of MuSK-dependent intracellular granules containing phosphorylated SMAD1/5/8 ( fig. S6) . Finally, as an ALK binding protein, MuSK could shape the composition and thus the output of BMP signaling complexes in myogenic cells.
MuSK-dependent BMP signaling modulates the muscle cell response to mAChR-mediated Ca 2+ signaling through the regulation of RGS4 production. RGS proteins stimulate G a GTPase activity, thus diminishing G protein signaling (31) . Activation of G aq -coupled mAChRs by carbachol results in a transient increase in Ca 2+ that was inhibited by BMP4 treatment (Fig. 6) . Direct pharmacological blockade of RGS4 reversed this inhibition, suggesting a direct link between the MuSK-BMP pathway and the cellular response to mAChR activation. However, it should be noted that the complete mechanism by which MuSK-dependent BMP signaling induces Rgs4 expression remains to be elucidated.
MuSK may regulate multiple subclasses of the BMP superfamily. For example, MuSK binds ALK4 (Fig. 4) , a type I activin receptor and one of the preferred type I receptors for myostatin, a potent negative regulator of skeletal muscle growth (36) . Other RTKs may play a similar role in BMP signaling. For example, the RTK ROR2 has been reported to bind ALK6 in heterologous cells (10, 37, 38) .
The role of MuSK as a BMP co-receptor is mechanistically distinct from its function in synapse formation. Agrin, LRP4, and the tyrosine kinase activity of MuSK are absolutely required for NMJ formation and stability. Moreover, this pathway is restricted to differentiated muscle cells, and agrin-LRP4-MuSK-dependent AChR clustering does not require de novo transcription (39) . In contrast, the role of MuSK as a BMP co-receptor is characterized by a robust transcriptional response in both myoblasts and myotubes that requires neither its tyrosine kinase activity nor a juxtamembrane tyrosine that is critical for NMJ differentiation (Fig. 4) . Moreover, the MuSK Ig3 domain is dispensable for its ability to mediate AChR clustering (40) but is required for BMP binding (Fig. 1) . Although these two MuSK pathways are distinct, they could collaborate in fully differentiated synapses. For example, the expression of Dok7, which encodes an essential binding partner of MuSK in postsynaptic differentiation, is regulated in a MuSK-and BMP-dependent fashion (table S6) . Finally, the BMP pathway plays a critical role in the differentiation of nerve muscle synapses in Drosophila melanogaster (41) . However, in this case, the BMP ortholog Gbb acts as a muscle-derived retrograde signal to promote presynaptic differentiation (41, 42) .
The MuSK-BMP pathway could play a role in the regulation of myofiber size and composition. BMP signaling promotes muscle hypertrophy and counters denervation-induced atrophy (43) (44) (45) . After denervation or immobilization, MuSK abundance increases along the entire length of the muscle (46) , suggesting that MuSK plays a role in BMP-mediated signaling in these pathological contexts. MuSK is also present extrasynaptically in slow-oxidative muscle fibers (17) , and two slow-muscle genes, Myh15 and Car3, are stimulated by BMP in a MuSK-dependent manner. Finally, the BMP-MuSK pathway regulates the production of both COX2, which is important for myoblast proliferation, fusion, and growth (47) (48) (49) (50) , and RGS4, which can inhibit cell growth and myofilament organization in neonatal cardiac myocytes (51) .
The data presented here show that MuSK is a BMP co-receptor that modulates mAChR-mediated Ca 2+ signaling in myogenic cells as well as pathways important for muscle differentiation and size. Understanding such regulation could be beneficial for treating pathological conditions, such as Duchenne muscular dystrophy, insulin-resistant type 2 diabetes, and disuse atrophy (52) , in which muscle mass is lost or muscle function is compromised. Finally, future studies may also reveal whether MuSK modulates BMP signaling in nonmuscle tissues such as brain (18) .
MATERIALS AND METHODS
Antibodies and recombinant proteins
Purified recombinant human BMP4, ALK6-Fc, ALK3-Fc, ALK4-Fc, BMPRII-Fc, and TROY-Fc chimeras, mouse ALK2-Fc and ActRIIB-Fc chimeras, and rat agrin were obtained from R&D systems. Antibodies specific for MuSK, ALK3, ALK6, and BMP4 (both unlabeled and biotinylated) were obtained from R&D Systems. Streptavidin-HRP was obtained from Thermo and used at 1:15,000 dilution. Mouse HRP and human IgG(Fc) secondary antibodies were obtained from KPL and used at 1:400 dilution. SMAD5 and phosphorylated SMAD1/5/8 antibodies were obtained from Epitomics, and phosphotyrosine (4G10) antibody was obtained from EMD Millipore Corporation and used at 1:1000, 1:2000, and 1:1000 dilutions, respectively. Alexa Fluor 555-conjugated goat antibody against rabbit IgG was obtained from Invitrogen and used at 1:1000. Constructs encoding full-length and Ig3-lacking Fc-Fusion MuSK ectodomains were obtained from GenScript and were used at the indicated concentrations. A construct encoding the His-tagged MuSK ectodomain was expressed in human embryonic kidney (HEK) 293 PEAKrapid cells from the American Type Culture Collection, and secreted recombinant HisMuSK ectodomain was purified from the cell culture supernatant by immobilized nickel ion affinity chromatography. LDN-193189 was obtained from Stemgent and was used at 50 nM.
Mammalian cell culture and mice
Mouse C2C12BRA cells (18) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2% Lglutamine, and 1% penicillin-streptomycin and cultured at 37°C in 8% CO 2 . Immortalized myoblast cultures of wild-type mouse H-2Kb-tsA58 (53) and MuSK −/− and MuSK rescue lines [wild-type MuSK (B1), kinasedead MuSK (K608A), and MuSK Y553A] were cultured on gelatin-coated dishes in DMEM supplemented with 20% fetal bovine serum, 2% Lglutamine, 1% penicillin-streptomycin, 1% chicken embryo extract, and 1 U of interferon-g under permissive temperature at 33°C in 8% CO 2 . Myotubes were obtained by switching the confluent myoblast cultures to a medium with DMEM supplemented with 5% horse serum, 2% Lglutamine, and antibiotics at 37°C in 8% CO 2 . For the LDN-193189 treatments, myoblasts were treated with the drug (50 nM) for 30 min before BMP4 treatment, and the drug was kept in cultures during the course of the treatment. Soleus and extensor digitorum longus muscles were harvested from 5.5-week-old adult C57BL/6 mice. All protocols were conducted under accordance and with the formal approval of Brown University's Institutional Animal Care and Use Committee.
Luciferase reporter assays
C2C12BRA cells were plated in 96-well culture dishes at 4 × 10 3 to 5 × 10 3 cells per well and allowed to adhere overnight. The indicated recombinant proteins were premixed in DMEM containing 0.1% bovine serum albumin (BSA) for 20 min at 4°C, and the original culture medium was replaced with this solution. The cells were incubated for 8 hours and washed twice with phosphate-buffered saline (PBS) before the extracts were prepared with 1× cell lysis buffer (50 ml per well; Roche). The lysate (40 ml) was transferred to an opaque white 96-well microplate and mixed with 100 ml of luciferase substrate (Roche). The luciferase activity was read in a luminometer and reported as relative luciferase unit (RLU), which is the value for each condition after subtraction of mock treatment (no-BMP4) value and normalization to BMP4-only condition. All assays were performed in eight biological replicates and repeated at least two times with similar results.
For testing of supernatants in the solution-binding experiments, the indicated recombinant proteins were premixed in DMEM containing 0.1% BSA for 2 hours at 4°C, followed by addition of magnetic nickel-bound beads (Promega) and a further 2-hour incubation at 4°C. The same protocol detailed above was followed after this step to test BMP4 activity. The average value of untreated cells was subtracted from each condition, and everything was normalized to BMP4-only condition (100% activity).
Immunoprecipitation and coimmunoprecipitation
For MuSK immunoprecipitation, treated H-2Kb-tsA58 myotubes were lysed in extraction buffer [10 mM tris-HCl (pH 7.4), 1% Triton X-100, 0.5% NP-40, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride and 1× EDTA-free protease inhibitor cocktail (Roche cOmplete)]. For MuSK-ALK coimmunoprecipitation, H-2Kb-tsA58 myotubes were lysed in extraction buffer [10 mM tris-HCl (pH 7.4), 1% Triton X-100, 150 mM NaCl, 1 mM sodium orthovanadate, 10 mM sodium fluoride, and 1× EDTA-free protease inhibitor cocktail (Roche cOmplete)]. Lysates for immunoprecipitation and coimmunoprecipitation experiments were precleared with protein Gbound magnetic beads (Invitrogen); bicinchoninic acid assay (BCA) was used to quantify total protein amounts in the lysates (Pierce). For immunoprecipitation experiments, lysates with equal amounts of total protein and the MuSK-specific antibody were mixed and tumbled overnight at 4°C. For coimmunoprecipitation, pooled lysates from three to four T75 flasks were divided into equal volumes for the pull-downs with ALK3-and ALK6-specific antibodies or the control (normal IgG) antibody overnight at 4°C. After the addition of protein G-bound magnetic beads, lysates were tumbled for 4 to 6 hours at 4°C. The beads were washed with extraction buffer, and 2× sample buffer was added for elution of the immunoprecipitated proteins from the beads. Proteins were eluted by boiling the samples at 98°C for 5 min. Western blots were run for the samples as indicated below.
Western blots
For phosphorylated SMAD1/5/8 Western blotting, lysates from cells that were serum-deprived in DMEM containing 0.1% BSA for 5 to 6 hours and treated with BMP4 for 15 min were prepared in extraction buffer containing 10 mM tris-HCl (pH 7.4), 1% Triton X-100, 0.5% NP-40, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride, and 1× EDTA-free protease inhibitor cocktail (Roche cOmplete). Lysates were cleared by centrifugation at 13,000 rpm for 10 min at 4°C. Total protein was measured by BCA (Pierce). Equal amounts of protein were separated on 5 to 15% gradient SDS-polyacrylamide gel electrophoresis gels and immunoblotted with phosphorylated SMAD1/5/8 antibody (Cell Signaling Technology). Antiphosphotyrosine antibody (4G10) was used for immunoprecipitations of phosphorylated MuSK (Millipore). Membranes were then stripped and reprobed with SMAD1/5/8 antibody (Cell Signaling Technology) or MuSK antibody for phospho-MuSK immunoprecipitation (R&D Systems).
ELISA assays
For MuSK binding to BMP4, recombinant MuSK proteins (FL-ecto-MuSK and DIg3-ecto-MuSK) were immobilized on 96-well plates at 2 mg/ml overnight. Plates were blocked with 1% BSA in PBS and incubated with BMP4 (0 to 200 nM). Bound BMP4 was detected with biotinylated anti-BMP4 antibody (R&D Systems) followed by streptavidin-conjugated HRP (Thermo). Graphs were generated with absorbance values, each data point representing the average of three independent ELISAs with four replicate wells for all data points in each independent assay. For MuSK binding to biglycan, His-tagged nonglycanated biglycan (54) was immobilized, and MuSK ectodomain Fc-fusion proteins (full-length MuSK and DIg3 MuSK) were incubated with immobilized biglycan. Bound MuSK was detected with HRP-conjugated human Fc antibody. For MuSK binding to ALK6, His-tagged MuSK was immobilized and Fc-fusion ALK3, ALK6, and TROY proteins were incubated with immobilized MuSK. Bound receptors were detected with HRPconjugated and Fc-specific anti-human IgG antibody (KPL).
RNA extraction, reverse transcription, and qRT-PCR
Total RNA was isolated from cells with TRIzol (Invitrogen), cleaned up and deoxyribonuclease-treated in Qiagen RNeasy columns, and reversetranscribed into first-strand complementary DNA (cDNA) (Invitrogen). The qRT-PCR reaction consisted of initial incubation at 50°C for 2 min and denaturation at 95°C for 5 min. The cycling parameters were as follows: 95°C for 15 s and 60°C for 30 s. After 40 cycles, the reactions underwent a final dissociation cycle as follows: 95°C for 15 s, 60°C for 1 min, 95°C for 15 s, and 60°C for 15 s. Expression of each gene was normalized to 18S rRNA expression. The primer sequences used in qRT-PCR reactions were as follows: 5′-AGGAGTGGGCCTGCGGCTTA-3′ and 5′-AACGGCCATGCACCACCACC-3′ for mouse 18S rRNA; 5′-GGG-ATCTCTGGGAAAGACAC-3′ and 5′-TCTCTGGAGGCTGAAAGGTG-3′ for mouse Id1; 5′-GTATTTCCATCGCTCCTTGG-3′ and 5′-TGA-GGCCTATAAAGCACATGG-3′ for mouse Rgs4; 5′-TCTTCGGGCAA-GAAACTCTG-3′ and 5′-TTGCATGTGACTGCTTCTCC-3′ for mouse Car3; 5′-CAGGCACACTTCTCCTTTCC-3′ and 5′-CCTTCCTCATCATG-GACCAG-3′ for mouse Myh15; 5′-CATCAGCTGGATTGAAAACG-3′ and 5′-CAGCCTTTGCGGTACTGAAC-3′ for mouse MuSK; 5′-TCC-TCTCTGTTGCGTGTGTC-3′ and 5′-CGTTAAGCAACAGGACATGC-3′ for mouse Ptger4; 5′-CGCTGATTGGGTTTTCGTAG-3′ and 5′-CCTGA-GCTGAGGTTTTCCTG-3′ for mouse Ptgs2; 5′-CTTTGGGGATAT-CGTTGCTG-3′ and 5′-GCTGGCTAACTCTGGGACT-3′ for mouse Fabp7.
Microarrays and bioinformatic analysis
Total RNA from cultures of wild-type and MuSK −/− myoblasts and myotubes treated with BMP4 (25 ng/ml) for 8 hours was prepared by the TRIzol extraction method (Invitrogen). The quality of the input RNA (150 to 200 ng) for the microarrays was checked by a bioanalyzer [RNA integrity number (RIN) scores of >9]. Total RNA was converted to double-stranded cDNA and then in vitro-transcribed overnight using the Whole Transcript expression kit from Invitrogen (catalog #4411981). After cleanup, 10 mg of in vitrotranscribed cRNA was converted to deoxyuridine triphosphate-labeled cDNA, and 5.5 mg of the generated single-stranded cDNA was enzymatically fragmented followed by TdT-mediated biotin end-labeling using the Whole Transcript terminal labeling kit (Affymetrix, catalog #900670). Successful fragmentation (~75 nucleotides) was demonstrated on the bioanalyzer with RIN scores of 2.6. About 2.5 mg of cDNA was hybridized at 45°C to Affymetrix Mouse 1.0 Gene ST chip (catalog #901168). The arrays were washed and stained following the Affymetrix standard protocol and scanned on an Affymetrix 3000 7G scanner.
The Affymetrix Expression console was used to analyze the overall performance and quality of the arrays, and Partek Genomics Suite was used to detect differentially expressed genes. To identify genes differentially expressed between samples, we used a combination of two selection criteria: ±1.5-fold change and FDR-adjusted P < 0.05, such that the FDR was controlled at 5%. FDR amounts to a statistical adjustment to allow for multiple testing, whereas the fold change cutoff serves as an additional filter to identify biologically meaningful hits. GO analysis was performed using the DAVID (Database for Annotation, Visualization, and Integrated Discovery) database. (55)
Surface plasmon resonance
The binding affinities and kinetic parameters between BMPs and MuSK were determined by SPR spectroscopy using the BIAcore3000 optical biosensor instrument (GE Healthcare Life Sciences). The carboxymethylated surface of the sensor chip (CM5) was activated with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride. The CM5 chip contains four flow cells, and among these four cells, three were used for the assay. Flow cell 1 was used as a control surface, whereas flow cells 2, 3, and 4 were used as test surfaces. Recombinant human BMP2 (2466 RU), BMP4 (2108 RU), and BMP7 (2050 RU) were covalently coupled in flow cells 2, 3, and 4, respectively. Unreacted active ester groups were blocked with 1 M ethanolamine hydrochloride (pH 8.5). The control flow cell 1 was treated in an identical manner but without coupling protein. The binding assays were carried out at 25°C in 20 mM Hepes buffer (pH 7.5), 500 mM NaCl, 3.4 mM EDTA, and 0.005% surfactant P-20. Various concentrations of MuSK were applied over the biosensor chip at a flow rate of 20 ml/min for 360 s to measure the association phase followed by buffer only for 600 s to measure the dissociation phase. The sensor chip was regenerated with four short pulses of guanidine hydrochloride (2 M) at 100 ml/min. Data were evaluated using the software BIAevaluation 4.1.1 (BIAcore AB). Because primary amine coupling can result in a heterogeneous population of BMP ligand with certain molecules being affected by the coupling process, SPR sensorgrams were globally analyzed using a distribution model for continuous affinity and rate constant analysis (k on and k off ) with the program EVILFIT (56) . This model helps account for BMP molecules that have reduced affinity due to the coupling procedure.
Calcium imaging
H-2Kb-tsA58 myoblasts plated on glass coverslips and pretreated with BMP4 (25 ng/ml) or vehicle for 4 hours were incubated in the dark for 20 min in extracellular solution with 2 mM Fluo-4 AM (Molecular Probes/ Life Technologies) and 250 mM sulfinpyrazone (uridine 5'-diphosphoglucuronosyltransferase inhibitor, Sigma-Aldrich) to prevent the loss of Fluo-4 from cells. Coverslips were then transferred to the imaging chamber, and time-lapse fluorescence images were acquired every 2 s using MetaMorph software (Molecular Devices). The M1 receptor agonist carbachol (50 mM) was added after acquiring 25 baseline images (50 s), followed by addition of ionomycin (2 mM) to elicit maximal Fluo-4 fluorescence, used for normalization. The RGS4 inhibitor 11b (CCG-203769, 3 mM) was added together with Fluo-4 AM and sulfinpyrazone for 20 min.
For each Ca 2+ imaging experiment, the fluorescence intensity of more than seven individual cells from each coverslip was measured as a function of time and was averaged. Fluorescence intensities were quantified and normalized as F norm(t) = (F cell(t) − F min )/(F iono − F min ), where F cell is the fluorescence of an intracellular region of interest (>25% of total cell area), F iono is the maximal fluorescence with ionomycin, and F min is the baseline fluorescence before stimulation. Carbachol-induced changes in fluorescence intensity were quantified using MetaMorph (Molecular Devices), MATLAB (MathWorks), and Excel software (Microsoft).
Statistical analysis
The average values of the replicate experiments are given as means ± SD/ SEM. Statistical differences among the experimental groups were analyzed by one-way ANOVA for multiple comparisons and by unpaired, two-sided Student's t test when comparing two experimental groups. To prevent the identification of false-positives due to increased number of comparisons, ANOVA results were corrected by the conservative Bonferroni post hoc test. Significance was defined as P < 0.05 (***P < 0.0001; **P < 0.01; *P < 0.05).
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